Arvinas, Inc. is a biotechnology company developing drugs designed to eliminate disease-causing proteins using PROTAC technology, which leverages the body's natural protein disposal mechanisms. The company's pipeline includes candidates targeting neurodegenerative diseases like Parkinson's, various cancers including those with specific genetic mutations, hormone-receptor-related cancers, and prostate cancer, with several programs in clinical development. Arvinas collaborates with major pharmaceutical partners including Pfizer, Genentech, Roche, and Bayer.

entry readiness 76 · GOOD SETUP · exit proximity 0

Value area 7.48–9.92 · 71% of 120d volume overhead · heavy supply